🚀 VC round data is live in beta, check it out!
Esperion Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Esperion Therapeutics and similar public comparables like Aarti Pharmalabs, Pharmicell, Zentiva, MiMedx Group and more.
Esperion Therapeutics Overview
About Esperion Therapeutics
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Founded
2008
HQ
Employees
304
Website
Sectors
Financials (LTM)
EV
$910M
Esperion Therapeutics Financials
Esperion Therapeutics reported last 12-month revenue of $404M and EBITDA of $70M.
In the same LTM period, Esperion Therapeutics generated $285M in gross profit, $70M in EBITDA, and had net loss of ($14M).
Revenue (LTM)
Esperion Therapeutics P&L
In the most recent fiscal year, Esperion Therapeutics reported revenue of $403M and EBITDA of $64M.
Esperion Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $404M | XXX | $403M | XXX | XXX | XXX |
| Gross Profit | $285M | XXX | $274M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $70M | XXX | $64M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 16% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | ($14M) | XXX | ($23M) | XXX | XXX | XXX |
| Net Margin | (3%) | XXX | (6%) | XXX | XXX | XXX |
| Net Debt | — | — | $82M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Esperion Therapeutics Stock Performance
Esperion Therapeutics has current market cap of $696M, and enterprise value of $910M.
Market Cap Evolution
Esperion Therapeutics' stock price is $2.91.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $910M | $696M | 0.0% | XXX | XXX | XXX | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEsperion Therapeutics Valuation Multiples
Esperion Therapeutics trades at 2.3x EV/Revenue multiple, and 13.0x EV/EBITDA.
EV / Revenue (LTM)
Esperion Therapeutics Financial Valuation Multiples
As of March 21, 2026, Esperion Therapeutics has market cap of $696M and EV of $910M.
Equity research analysts estimate Esperion Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Esperion Therapeutics has a P/E ratio of (50.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $696M | XXX | $696M | XXX | XXX | XXX |
| EV (current) | $910M | XXX | $910M | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 13.0x | XXX | 14.2x | XXX | XXX | XXX |
| EV/EBIT | 13.4x | XXX | 15.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.2x | XXX | 3.3x | XXX | XXX | XXX |
| P/E | (50.3x) | XXX | (30.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (69.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Esperion Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Esperion Therapeutics Margins & Growth Rates
Esperion Therapeutics' revenue in the last 12 month grew by 3%.
Esperion Therapeutics' revenue per employee in the last FY averaged $1.3M.
Esperion Therapeutics' rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Esperion Therapeutics' rule of X is 25% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Esperion Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 29% | XXX | 64% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 42% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Esperion Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aarti Pharmalabs | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharmicell | XXX | XXX | XXX | XXX | XXX | XXX |
| Zentiva | XXX | XXX | XXX | XXX | XXX | XXX |
| MiMedx Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Guizhou Sanli | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Esperion Therapeutics M&A Activity
Esperion Therapeutics acquired XXX companies to date.
Last acquisition by Esperion Therapeutics was on XXXXXXXX, XXXXX. Esperion Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Esperion Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEsperion Therapeutics Investment Activity
Esperion Therapeutics invested in XXX companies to date.
Esperion Therapeutics made its latest investment on XXXXXXXX, XXXXX. Esperion Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Esperion Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Esperion Therapeutics
| When was Esperion Therapeutics founded? | Esperion Therapeutics was founded in 2008. |
| Where is Esperion Therapeutics headquartered? | Esperion Therapeutics is headquartered in United States. |
| How many employees does Esperion Therapeutics have? | As of today, Esperion Therapeutics has over 304 employees. |
| Who is the CEO of Esperion Therapeutics? | Esperion Therapeutics' CEO is Sheldon L. Koenig. |
| Is Esperion Therapeutics publicly listed? | Yes, Esperion Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Esperion Therapeutics? | Esperion Therapeutics trades under ESPR ticker. |
| When did Esperion Therapeutics go public? | Esperion Therapeutics went public in 2013. |
| Who are competitors of Esperion Therapeutics? | Esperion Therapeutics main competitors are Aarti Pharmalabs, Pharmicell, Zentiva, MiMedx Group. |
| What is the current market cap of Esperion Therapeutics? | Esperion Therapeutics' current market cap is $696M. |
| What is the current revenue of Esperion Therapeutics? | Esperion Therapeutics' last 12 months revenue is $404M. |
| What is the current revenue growth of Esperion Therapeutics? | Esperion Therapeutics revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Esperion Therapeutics? | Current revenue multiple of Esperion Therapeutics is 2.3x. |
| Is Esperion Therapeutics profitable? | Yes, Esperion Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Esperion Therapeutics? | Esperion Therapeutics' last 12 months EBITDA is $70M. |
| What is Esperion Therapeutics' EBITDA margin? | Esperion Therapeutics' last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Esperion Therapeutics? | Current EBITDA multiple of Esperion Therapeutics is 13.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.